Please ensure Javascript is enabled for purposes of website accessibility

Forget AMC and Gamestop: These 2 Popular Robinhood Stocks Are Better Buys

By Prosper Junior Bakiny - Mar 16, 2021 at 6:15AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

No need to invest in faltering businesses -- these two winning companies are better bets.

The commission-free trading platform Robinhood is popular among novice investors, millennials, and traders. These groups of market enthusiasts can certainly pick excellent stocks, as evidenced by the list of the 100 most popular stocks on the platform. However, some of the stocks on that list are head-scratchers. For instance, GameStop (GME -3.56%) and AMC Entertainment (AMC -8.03%) are among the top 20 most commonly held stocks on the app as of this writing. 

Both of these businesses are struggling, in part due to their reliance on brick-and-mortar operations, which were severely impacted by the pandemic. Further, both AMC and Gamestop were at the center of the now (in)famous short-squeeze fiasco orchestrated by traders from Reddit's r/WallStreetBets. Investors would be better off staying away from these two unpredictable companies and instead purchasing shares of Robinhood stocks with solid futures ahead of them. Two such companies worth considering are Pfizer (PFE 3.59%) and Netflix (NFLX 1.56%)

^SPX Chart

^SPX data by YCharts

1. Pfizer

You've probably heard a lot about Pfizer in the past few months. The company and its partner, BioNTech, developed BNT162b2, and received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA) in December, becoming the first authorized COVID-19 vaccine in the U.S. BNT162b2 has also been approved in the European Union.

While Pfizer and BioNTech have to share the vaccine supply gameboard with several other companies, including Johnson & Johnson, AstraZeneca, and Moderna, the market (i.e., the entire world) is large enough for there to be multiple winners. In other words, BNT162b2 will contribute meaningfully to Pfizer's top line, especially since there is evidence of it being effective against some of the newer variants of the virus. 

But the company's lineup is much bigger than just this one vaccine. Some of Pfizer's top-performing products include anticoagulant Eliquis and cancer treatments Ibrance and Xtandi. Sales of Eliquis for fiscal year 2020 (ended Dec. 31) were $4.9 billion, a 17% year-over-year increase. Ibrance's revenue jumped by 9% year over year to $5.4 billion, while Xtandi's sales came in at roughly $1 billion, representing 22% growth from fiscal year 2019.

Pfizer also boasts 95 programs in its pipeline, including 24 ongoing phase 3 studies. Pfizer is well-positioned to keep adding new revenue sources to its lineup every year. Lastly, it is worth noting that Pfizer spun-off its off-patent medicine unit Upjohn to the company formerly known as Mylan. The combined entity of Mylan and Upjohn is called Viatris, and it started trading on the market on Nov. 17.

Pfizer decided to make this move because Upjohn's declining sales were hurting its bottom line. The company can now focus on its more profitable biopharma business. This focus should help Pfizer improve its financial results, which will help its stock recover from its underperformance relative to the market in the past year. 

With a more focused business, a short-term catalyst in the form of its coronavirus vaccine, other medicines with growing sales, and a rich pipeline to keep revenue sources coming, this pharma stock looks like a much better long-term bet than AMC or GameStop. 

Female medical worker wearing green scrubs and a face mask administers a vaccine to a mature female patient, who is also wearing a face mask.

Image source: Getty Images

2. Netflix 

Netflix is already one of the leading streaming video platforms in the world, but the company isn't done growing. What are the opportunities ahead for the tech giant? First, the company is looking to add even more users to its platform. As of its fourth quarter ending Dec. 31, the company had 8.51 million net new subscribers. It ended the period with a total of 203.7 million paid subscriptions, representing a year-over-year increase of 21.9%. Netflix thinks it will add 6 million new subscribers in the first quarter of 2021.

And the streaming services industry as a whole has a long runway for growth. According to Grand View Research, this market was worth 50.1 billion in 2020, and it is projected to expand at a compound annual growth rate (CAGR) of 21% between 2021 and 2028.

As one of the most recognizable names in this segment, Netflix is well-positioned to profit, especially since competing streaming platforms are more than capable of coexisting. One of the most powerful weapons in these platforms' arsenals is original content, and Netflix has been pouring money into original series and movies in the hopes of building a library people will want to keep coming back to.

Hand holding TV remote and browsing through a library of videos.

Image source: Getty Images.

These investments have played an important role in the company's success in recent years. Since the content on Netflix is different from that of some of its peers, many customers are more than happy to pay for subscriptions to several companies in this space. The long-term plan for Netflix is simple: Replace regular TV.

The company offers several advantages over cable: no ads, no long-term contracts, and on-demand movies and series streaming on any device. And while some cable providers have started to adapt to the new paradigm, Netflix is well on its way to continue its long winning streak in the streaming industry. Those factors make the company's stock worth a buy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
$52.47 (3.59%) $1.82
Netflix, Inc. Stock Quote
Netflix, Inc.
$186.35 (1.56%) $2.87
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.21 (2.59%) $1.67
Johnson & Johnson Stock Quote
Johnson & Johnson
$176.98 (1.75%) $3.04
GameStop Corp. Stock Quote
GameStop Corp.
$95.66 (-3.56%) $-3.53
AMC Entertainment Holdings, Inc. Stock Quote
AMC Entertainment Holdings, Inc.
$12.03 (-8.03%) $-1.05
BioNTech SE Stock Quote
BioNTech SE
$163.00 (-2.90%) $-4.87
Moderna, Inc. Stock Quote
Moderna, Inc.
$136.25 (-4.97%) $-7.13
Viatris Inc. Stock Quote
Viatris Inc.
$11.80 (0.94%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.